Designing next generation immunotherapies based on gene-edited CAR T-cells
Cellerant is developing novel innate and adaptive immunotherapies for oncology and blood-related disorders, including cell-based and antibody therapeutics.
CellSight's makes imaging tools to assess the response to immunotherapy..
Develops technology to activate the innate and adaptive arms of the immune system to recognize and ultimately destroy tumor cells.
CisThera’s mission is to develop innovative therapeutics to treat cancer, autoimmune diseases, as well as chronic kidney and liver diseases.
Develops molecules to activate Toll like receptors. These can be used to stimulate the innate immune system.
Compugen, via its wholly-owned subsidiary Compugen USA, Inc., is developing therapeutic antibodies against selected target proteins both for cancer immunotherapy and antibody-drug conjugate ...
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel agents that target the immune system to treat patients with cancer.
Develops cancer immunotherapies, drug conjugates (PDCs), T-cell engaging Probody bispecifics and ProCAR-NK cell therapies based on Protease-Activated Antibodies, 'Probodies'
Immunotherapy treatment for prostate cancer.
Develops glutamine antagonists "immune-metabolism" to improve immune responses against cancer tumors.
Elicio is re-engineering the body’s immune response to cancer by combining materials science and immunology. Elicio is engineering potent vaccines and immunotherapies to defeat an array of ...
Enlivex Therapeutics is a clinical-stage company focused on specialized cell immunotherapy. Their intent is to develop and commercialize an allogeneic drug pipeline designed to rebalance all ...
Focused on therapies for cancer and inflammatory diseases
Activating the immune system to eradicate cancer. Focuses on regulatory T cells.
Committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity.
Genenta is developing a gene transfer strategy into hematopoietic cells to target a specific anti-tumor protein. A disabled virus vector delivers the gene into the cells. A combination of ...
Genexine is a clinical stage biotechnology company focused on the development and commercialization of innovative immunotherapeutics and next generation novel long-acting biologics
Glycostem is an innovator in allogeneic cellular immunotherapy using Natural Killer (NK) cells for treatment of leukemia, lymphoma and solid tumors.
Develops anti-cancer immunotherapies
Single cell technologies for drug discovery. Neoantigen screening platform.
Their mission is to reprogram the immune system to help overcome cancer and infectious diseases. We do this by using a technology that “supercharges” the natural ability of the immune system to ...
Advancing first-in-class immunotherapy product candidates in oncology, as well as infectious and allergic diseases.
Engineers B cells through gene therapy to produce proteins that combat disease.
Our scientific innovation is based on a unique competency in medicinal chemistry, which is seamlessly integrated into a discovery process that is tailored to individual program needs. We have ...
Develops DNA vaccines and antigen-targeting immunotherapy to treat cancer and viral infections.
Invectys focuses on the development of anti-cancer therapeutic approaches in immunotherapy.
IOVANCE Biotherapeutics is focused on the development and commercialization of autologous cellular immunotherapies optimizing personalized, tumor-directed Tumor Infiltrating Lymphocytes (TIL). ...